2016-03-07 20:36:30 UTC

AGA Institute-AASLD GastroSlides Unit on Liver Cancer

About

Overview

Liver Cancer is separated into the following general sections: Part I: Epidemiology, Part II: Screening, Part III: Diagnosis, Part IV: Pathology, Part V: Pathogenesis, Part VI: Treatment, Part VII: Illustrative Cases.

Download Liver Cancer slides.

Description

This newly updated unit contains 264 images that illustrate epidemiological trends, causes, pathogenesis, screening, diagnosis and management of liver cancer, primarily hepatocellular carcinoma. The outstanding photographs, micrographs and illustrations explain important concepts in our understanding of the underlying pathophysiology of liver cancer. Management algorithms for this dire complication of advanced liver disease will aid the clinician in counseling and caring for patients. Images, including graphic representations of data from key studies, are accompanied by explanatory legends that contain recent literature citations, thereby providing a unique teaching and self-educational resource. Clinical cases provide a framework for using the slides for self-education and to teach practicing clinicians, fellows, residents and medical students. The senior author, Hashem B. El-Serag, MD, MPH, is associate professor of medicine, Baylor College of Medicine, Houston, TX.

GastroSlides images also cover a number of GI and liver disease topics. 

Who Should Take this Course

Clinical cases provide a framework for using the slides for self-education and to teach practicing clinicians, fellows, residents and medical students.

Takeaways

After reviewing the slides, the learner will be able to:

  • Describe trends in the prevalence and incidence of hepatocellular carcinoma (HCC).
  • Recognize most important risk factors for developing HCC.
  • Discuss the clinical implications and importance of screening and surveillance strategies in monitoring patient populations at high risk for HCC.
  • Describe HCC staging.
  • Describe current pharmacologic, surgical and transplant treatment options for HCC.
  • Recount recent clinical trial results relevant to the treatment of HCC.
  • Discuss ongoing research in multimodality treatment approaches for HCC. 

About the Instructors

Senior Author

Hashem B. El-Serag, MD, MPH
Associate Professor of Medicine
Baylor College of Medicine
Houston, TX

Co-Authors

Jorge Marrero, MD
Assistant Professor of Medicine
University of Michigan
Ann Arbor, MI

K. Rajendar Reddy, MD
Professor of Medicine and Surgery
University of Pennsylvania
Philadelphia, PA

Lewis Roberts, MD, PhD
Associate Professor of Medicine
Mayo Clinic College of Medicine
Rochester, MN

Snorri S.Thorgeirsson, MD, PhD
Chief, Laboratory of Experimental Carcinogenesis
Center for Cancer Research
National Cancer Institute, NIH
Bethesda, MD

Artists

Stan Coffman
Jerry Schoendorf, MAMS
Chapel Hill, NC

Sponsor

Developed in collaboration with AASLD and supported by an educational grant from Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals.

Published Date and Terms of Use

The content included in this GastroSlide set, Liver Cancer, was published on January 12, 2010. This slide set has not been updated since the date of publication and is provided “as is.” It is the learner's responsibility to evaluate the accuracy of any information found within these educational materials.

The intent of this series is to provide individual clinicians and educators with materials to use in their educational activities, such as lecturing at continuing medical education meetings and for self-education. AGA encourages all uses of GastroSlide materials consistent with this objective.

Materials are to be displayed in the same content and form as the original with no alterations unless approved by AGA. No materials may be reproduced for any purpose without written permission of AGA. Materials may only be used for educational purposes and may not be used to promote or advertise any pharmaceutical, medical device or organization.

More on Autoimmune Hepatitis Liver Disease

Inflammation Contributes to the Development of Anemia

Nov. 17, 2016

The process involves increased liver expression of a microRNA that reduces production of erythropoietin in the kidney, according to a study in Gastroenterology.

DDSEP 8® Features Latest HCV Updates

Aug. 11, 2016

Contributor Dr. Carl Berg offers his take on why the latest DDSEP offering is among the best.

Hydrazine Shows Potential as Therapy for Acute Alcoholic Liver Disease

July 5, 2016

New from CMGH: hydrazine protected mice from the damaging effects of alcohol.